Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.11.5915

What is the Mechanism of Progression with Trastuzumab Treatment - Escape or Resistance?  

Sendur, Mehmet Ali Nahit (Ankara Numune Education and Research Hospital)
Aksoy, Sercan (Department of Medical Oncology, Hacettepe University Institute of Oncology)
Ozdemir, Nuriye Yildirim (Ankara Numune Education and Research Hospital)
Zengin, Nurullah (Ankara Numune Education and Research Hospital)
Altundag, Kadri (Department of Medical Oncology, Hacettepe University Institute of Oncology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.11, 2012 , pp. 5915-5916 More about this Journal
Abstract
Human epidermal growth factor receptor (HER) 2 overexpression, observed in 20-25 percent of invasive breast cancers, is well known to be associated with a more aggressive phenotype and poor prognosis, with resistance to certain chemotherapeutic agents. The majority of patients with metastatic breast cancer who initially respond to trastuzumab, demonstrate disease progression within 1 year of treatment initiation. Furthermore, lack of response in some patients and relapse during the course of therapy, continue to challenge researchers and clinicians. A better understanding of the fundamental mechanisms of trastuzumab action is required so that new therapies directed at HER2 can be developed. We present here findings for mechanisms, both of Trastuzumab action and clinical resistance or escape.
Keywords
Breast cancer; anti-HER2 treatment; trastuzumab; lapatinib;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Adams CW, Allison DE, Flagella K, et al (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunology -Immunotherapy, 55, 717-7.   DOI
2 Bailey TA, Luan H, Clubb RJ, et al (2011). Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinogenesis, 10, 8.   DOI
3 Baselga J, Bradbury I, Eidtmann H, et al (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 18, 633-0.
4 Baselga J, Cortes J, Kim SB, et al (2011). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England J Med, 366, 109-9
5 Gianni L, Pienkowski T, Im YH, et al. (2011). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet Oncology, 13, 25-2
6 Marty M, Cognetti F, Maraninchi D, et al (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clinical Oncology, 23, 4265-4.   DOI
7 Montemurro F, Valabrega G, Aglietta M (2007). Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy, 7, 257-8.   DOI
8 Nahta R, Hung MC, Esteva FJ (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 64, 2343-6.   DOI
9 Ross JS, Slodkowska EA, Symmans WF, et al (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist, 14, 320-8.   DOI   ScienceOn
10 Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England J Med, 344, 783-2.   DOI   ScienceOn
11 Tortora, G (2011). Mechanisms of Resistance to HER2 Target Therapy. J National Cancer Institute, 95-8.
12 Tovey SM, Witton CJ, Bartlett JM, et al (2004). Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast cancer Res, 6, 246-1.   DOI
13 Wu Y, Amonkar MM, Sherrill BH, et al (2011). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Eur Society for Med Oncology, 22, 2582-90.